How do patients feel after switching to HIV injections?
This study tracks how people living with HIV feel after switching to a two-shot injection (Cabotegravir and Rilpivirine) given every two months. It collects your feedback on quality of life and symptoms to see how the new treatment works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have HIV-1 and your viral load must have been undetectable (below 50 copies/mL) for the past 6 months or longer.
- You must be switching from your current HIV pills to the long-acting injectable combo (Cabotegravir + Rilpivirine) at the same visit you join the study.
- You must be able to read and answer questionnaires in French.
- You cannot be pregnant or breastfeeding, and must not have known resistance or a serious allergy to Cabotegravir or Rilpivirine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people living with HIV feel (quality of life) and how well their virus is controlled after they finish a long-acting injectable treatment with cabotegravir and rilpivirine. It's a follow-up to see if this easier treatment helps people stay healthy and feel better.
This study looks at switching people with HIV from daily or regular oral medicine to long-acting injections (cabotegravir plus rilpivirine). It may help those who are well-controlled on current therapy who prefer injections and can safely take this combination.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Hear when a new Quality of Life trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.